Viridian Therapeutics reports 3Q loss of $101.2 million
Story updates
12:11:28 PM UTC
SquawkNews
Viridian Therapeutics 3Q Loss/Shr 81c >VRDN
12:15:08 PM UTC
SquawkNews
Viridian Therapeutics reported third-quarter 2026 net product revenue of $24.7 million and a net loss of $101.2 million. The company ended September with $955.2 million in cash, cash equivalents and marketable securities. Its Lumvoa launch had more than 100 patients on therapy at quarter-end.Financ…
12:19:48 PM UTC
SquawkNews
*-- Earnings Flash (VRDN) Viridian Therapeutics Posts Q3 Net Loss $0.81 a Share, vs. FactSet Est of $1.00 Loss
12:31:40 PM UTC
SquawkNews
Viridian Therapeutics reported third-quarter 2026 revenue of $25.8 million and a net loss of $101.2 million, as newly launched veligrotug generated its first U.S. product sales. The prior-year quarter included a $70 million Kissei upfront license payment.Financial HighlightsBusiness HighlightsOrigi…